New HIV-1 drug approved

EU to get new drug for treating HIV-1 infection.

A new once-daily integrase single tablet treatment designed to tackle the HIV-1 infection has received a nod of approval from the Committee for Medicinal Products for Human Use (CHMP), which will mean the drug could soon be endorsed throughout Europe.
The product Stribild, which was submitted to the branch of the European Medicines Agency (EMA) earlier this year by its developer Gilead Sciences, will now be reviewed by the European Commission before finally being put on sale throughout the 27-nation international community.
John Martin PhD, chairman and chief executive of Gilead Sciences, said the once-a-day nature of Stribild means that it has a huge potential for treating people with no known resistance to the components that make up the drug.
"We are pleased with today’s positive opinion from the CHMP and anticipate receiving a final decision from the European Commission on our application for Stribild in the coming months," he concluded.